Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Atlas Capital Advisors LLC

Atlas Capital Advisors LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.2% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 6,097 shares of the biopharmaceutical company’s stock after selling 1,007 shares during the period. Atlas Capital Advisors LLC’s holdings in Gilead Sciences were worth $447,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Altfest L J & Co. Inc. purchased a new position in Gilead Sciences during the fourth quarter worth $210,000. Federated Hermes Inc. raised its stake in Gilead Sciences by 4.9% in the 4th quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after purchasing an additional 175,925 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Gilead Sciences by 1.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock worth $589,873,000 after purchasing an additional 87,482 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new stake in shares of Gilead Sciences during the 4th quarter worth about $74,000. Finally, Eagle Asset Management Inc. raised its position in shares of Gilead Sciences by 23.6% in the fourth quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company’s stock valued at $25,724,000 after buying an additional 60,697 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Price Performance

GILD opened at $68.83 on Friday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The firm has a market cap of $85.75 billion, a price-to-earnings ratio of 191.19, a PEG ratio of 2.96 and a beta of 0.20. The company has a fifty day simple moving average of $65.89 and a 200 day simple moving average of $72.75.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same period in the previous year, the company earned $1.37 earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. Equities research analysts expect that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were paid a $0.77 dividend. The ex-dividend date was Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.47%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Analysts Set New Price Targets

Several research firms have commented on GILD. TD Cowen lowered their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. UBS Group reduced their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Wells Fargo & Company dropped their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research report on Wednesday, April 24th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $74.00 price target on shares of Gilead Sciences in a research report on Friday, June 14th. Twelve equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of “Hold” and a consensus price target of $83.47.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.